Table 2.
Comparison of underlying diseases in COVID-19 patients with GI or respiratory symptoms
| Variable | Total | GIA (n = 92) | RA (n = 184) | GIR (n = 151) | WGIR (n = 80) | P-value* |
|---|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | N (%) | ||
| Chronic cardiovascular disease | 60 (11.8) | 16 (17.4) | 23 (12.5) | 11 (7.3) | 10 (12.5) | 0.120 |
| Hypertension | 128 (25.3) | 28 (30.4) | 43 (23.5) | 35 (23.2) | 22 (27.5) | 0.539 |
| Hyperthyroidism | 1 (0.2) | 0 (0) | 1 (0.5) | 0 (0) | 0 (0) | 1.000† |
| Hypothyroidism | 13 (2.6) | 2 (2.2) | 5 (2.7) | 5 (3.3) | 1 (1.3) | 0.868† |
| G6PD deficiency | 5 (1.0) | 0 (0) | 2 (1.1) | 0 (0) | 3 (3.8) | 0.025† |
| Hyperlipidemia | 30 (5.9) | 6 (6.5) | 13 (7.1) | 9 (6.0) | 2 (2.5) | 0.537 |
| Malignant neoplasm | 8 (1.6) | 5 (5.4) | 0 (0) | 3 (2.0) | 0 (0) | 0.003† |
| Chronic hematologic disease | 9 (1.8) | 2 (2.2) | 3 (1.6) | 2 (1.3) | 2 (2.5) | 0.845† |
| Chronic neurologic disorder | 17 (3.4) | 4 (4.3) | 5 (2.7) | 5 (3.3) | 3 (3.8) | 0.869† |
| Obesity | 0 (0) | 3 (1.6) | 0 (0) | 0 (0) | 0 (0) | 0.268† |
| Chronic pulmonary disease | 12 (2.4) | 4 (4.3) | 4 (2.2) | 3 (2.0) | 1 (1.3) | 0.608† |
| Diabetes | 116 (22.9) | 24 (26.1) | 46 (25.0) | 24 (15.9) | 22 (27.5) | 0.090 |
| Asthma | 27 (5.3) | 3 (3.3) | 15 (8.2) | 6 (4.0) | 3 (3.8) | 0.264† |
| Chronic kidney disease | 29 (5.7) | 9 (9.8) | 7 (3.8) | 6 (4.0) | 7 (8.8) | 0.099 |
| Rheumatologic disorder | 7 (1.4) | 1 (1.1) | 0 (0) | 2 (1.3) | 4 (5.0) | 0.015† |
| Liver disease | 10 (2.0) | 6 (6.5) | 1 (0.5) | 1 (0.7) | 2 (2.5) | 0.005† |
RA respiratory alone, GIA gastrointestinal alone, GIR gastrointestinal and respiratory, WGIR without gastrointestinal or respiratory, N number, G6PD glucose-6-phosphate dehydrogenase
*Analyzed by Chi-squared test
†Analyzed by Fisher’s exact test